Start the conversation
The insiders just keep buying at our "liquid-biopsy" play TrovaGene Inc. (Nasdaq: TROV).
Shares of the San Diego-based company doubled in just three months after we recommended back on March 11.
When the stock sold off after that skyrocket rally, we told you not to worry. In fact, we recommended you turn that weakness into an opportunity - and accumulate more shares.
The corporate insiders seem to share our confident outlook.Full Story
This is premium content for Private Briefing subscribers only.